Opinion|Videos|August 5, 2024
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
3
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
4
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
5